In a new job - January 9, 2018
Targovax appoints new Chief Business Officer
Michael Bogenstaetter has been appointed as Targovax’s Chief Business Officer (CBO), taking up his new role in January 2018. Michael has 25 years’ experience in biotech and big pharma. During this time he held senior business development and strategy positions with Sanofi, Novartis and MDS. Michael has also worked as a consultant with The Boston […]
In a new job - December 14, 2017
Changes in Xbranes management team
Xbrane Biopharma announces that Carlo Colombo, Head of Production within Xbranes long acting injectable business, who forms a part of Xbranes management team, has on own initiative resigned. Carlo Colombo joined Xbrane Biopharma in January 2016 and has since then headed the commercial production of Spherotide. “It is with a heavy heart we see Carlo […]
In a new job - December 8, 2017
New VP and General Manager, North America at Nexstim
He will be effective in his new role from 1 January 2018. Steve Beller has experience in the US neuro-stimulation market where he was most recently Area Vice-President at Abbott Neuromodulation, managing a team of over 170 people in the Western half of the US. Prior to this, Mr. Beller held Senior Director and Regional […]
Biotech Business - December 7, 2017
Alligator expands its management team
Alligator Bioscience announces the expansion of its management team with the appointment of Charlotte A Russell, MD, PhD, as Chief Medical Officer and Peter Ellmark, PhD, Associate professor, as Vice President Discovery. Dr Russell will be responsible for leading Alligator’s clinical team in progressing the company’s immuno-oncology projects towards proof of concept in cancer patients. […]
In a new job - December 7, 2017
Progress for Pila Pharma
PILA PHARMA passes the start-up phase, prepares for efficacy trials and increases focus on ‘Effective and Affordable Medicine’ by electing the health economist Ulrikka Klarskov Kjær to the Board of Directors. The company, founded in 2014, now counts +10 core members and has thus passed the “start-up” phase. “We are about to move out of […]
In a new job - November 8, 2017
Zelluna Immunotherapy appoints Miguel Forte as CEO
One of the main initial tasks for Miguel will be to lead Zelluna through its next stage of development by driving clinical translation of the TCR pipeline, developing new international scientific and commercial partnerships and forging relationships with the international investor communities. This includes positioning Zelluna’s therapeutic candidates in the context of the adoptive cell […]
